S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

QLGN Qualigen Therapeutics Inc

0.3001

0.0051 (1.73%)

Last Updated: 04:00:33

Delayed by 15 minutes

Qualigen Therapeutics EPS beats by $0.01, beats on revenue

To read the full story on Seeking Alpha, click here.

Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Mar 2024 to May 2024

Click Here for more Qualigen Therapeutics Charts.

Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Qualigen Therapeutics Charts.

Qualigen Therapeutics Inc News

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Tuesday 16 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Tuesday 9 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 8 December 2023 (5 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 23 November 2023 (5 months ago) • Edgar (US Regulatory)

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Wednesday 15 November 2023 (6 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 9 November 2023 (6 months ago) • Edgar (US Regulatory)

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Wednesday 8 November 2023 (6 months ago) • GlobeNewswire Inc.

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
Monday 23 October 2023 (6 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 17 October 2023 (6 months ago) • Edgar (US Regulatory)

More Qualigen Therapeutics Inc News Articles

National Australia Bank

AUD vs US Dollar

Gold vs US Dollar

Commonwealth Bank Of Aus...

Westpac Banking

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions